Home > Result Summaries: Compounds > carvedilol Result Summaries: carvedilol GSKStudy ID Phase Title Summary (Download) 104257 Phase 1 A randomized, open-label, two period, period balanced, crossover study to estimate the relative bioavailability of an investigational drug compared to Coreg IR in healthy adult volunteers (0 citation(s)) 104851 Phase 4 Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR versus Twice Daily COREG Immediate Release (IR) On Measures of Compliance and Quality of Life in Patients with Heart Failure and Left Ventricular Systolic Dysfunction (0 citation(s)) 105517/003 Phase 1 Effect of carvedilol, administered orally at doses of 12.5, 25.0 and 50.0mg, on renal function in healthy subjects. (0 citation(s)) 105517/008 Phase 1 A pharmacokinetic study of carvedilol, 25 mg orally (SK&F 105517) to study the intra-subject variability and stereoselectivity of the pharmacokinetics in healthy subjects. (1 citation(s)) 105517/010 Phase 1 A dose proportionality study of carvedilol enantiomers following doses of racemic carvedilol (SK&F 105517 – capsules) of 6.25, 12.5, 25.0 and 37.5mg orally in healthy subjects. (1 citation(s)) 105517/011 Phase 1 A study to assess the acute effects of the co-administration of a single dose of 25mg carvedilol (SK&F 105517) on the plasma and urinary pharmacokinetics of digoxin after administration of a single dose of 0.5mg digoxin in normal man. (1 citation(s)) 105517/012 Phase 1 A study to assess the acute effects of the co-administration of a single dose of 25mg carvedilol (SK&F 105517) on the plasma and urinary pharmacokinetics of digoxin after administration of a single intravenous dose of 0.5mg digoxin in normal man. (1 citation(s)) 105517/013 Phase 1 A study to assess the acute effects of a standard meal on the pharmacokinetics of carvedilol, after administration of a single oral dose of 25mg carvedilol in normal man. (0 citation(s)) 105517/017 Phase 1 A study to investigate the pharmacokinetics of carvedilol enantiomers and the metabolites of carvedilol in poor and extensive metabolizers of debrisoquin. (0 citation(s)) 105517/021 Phase 2 A multicenter, double-blind, placebo-controlled comparison of Carvedilol (SK&F) 6.25 mg, 12.5 mg, and 25.0 mg administered twice daily in patients with mild and moderate hypertension. (0 citation(s)) 105517/022 Phase 2 A multicenter, double-blind, placebo-controlled comparison of carvedilol (SK&F 105517) 6.25mg, 12.5mg, 25mg, and 50mg administered once daily in patients with mild to moderate hypertension. (0 citation(s)) 105517/028 Phase 3 Placebo controlled assessment of carvedilol (SK&F 105517) and labetalol in black patients with mild to moderate hypertension. (0 citation(s)) 105517/030 Phase 1 A crossover study to compare the effect of carvedilol (SK&F 105517) and atenolol administered orally on renal hemodynamics in patients with mild to moderate essential hypertension. (0 citation(s)) 105517/031 Phase 2 A study to investigate the effect of renal insufficiency on the pharmacokinetics of carvedilol and the metabolites of carvedilol after single and multiple dose administration in patients with hypertension. (2 citation(s)) 105517/092 Phase 3 A multicenter, double-blind, placebo-controlled, randomized assessment of carvedilol (SK&F 105517) administered once (UID) or twice (BID) daily to patients with mild to moderate hypertension. (0 citation(s)) 105517/093 Phase 2 A multicenter, double-blind, placebo-controlled, randomized assessment of carvedilol (SK&F 105517) in patients whose blood pressure is uncontrolled on hydrochlorothiazide (HCTZ). (0 citation(s)) 105517/095 Phase 3 Carvedilol (SK&F 105517) versus atenolol and placebo in patients with mild to moderate essential hypertension. (1 citation(s)) 105517/099 Phase 3 A multicenter, double-blind, crossover study of three doses of carvedilol compared to placebo in patients with exertional angina. (0 citation(s)) 105517/100 Phase 3 A multicenter, double-blind, crossover study of carvedilol compared to placebo in patients with exertional angina. (0 citation(s)) 105517/121 Phase 1 Carvedilol – captopril interaction study. (0 citation(s)) 105517/123 Phase 3 Carvedilol-nifedipine S.R. interaction study. (1 citation(s)) 105517/124 Phase 3 Comparison of carvedilol to atenolol in the treatment of mild to moderate essential hypertension. (1 citation(s)) 105517/126 Phase 2 Comparison of carvedilol to acebutolol in the treatment of mild to moderate benign essential hypertension. (0 citation(s)) 105517/130 Phase 3 A comparison of the safety and efficacy of carvedilol with that of nifedipine s.r. in patients with mild to moderate benign essential hypertension. (0 citation(s)) 105517/132 Phase 3 A multicentre study of efficacy and safety of carvedilol in the elderly. (0 citation(s)) 105517/133 Phase 1 A double-blind, placebo controlled study of the acute effect of carvedilol and atenolol in patients uncontrolled on bendrofluazide. (0 citation(s)) 105517/136 Phase 3 A comparison of carvedilol with hydrochlorothiazide in the treatment of mild to moderate benign essential hypertension. (0 citation(s)) 105517/140 Phase 3 Comparison of carvedilol to captopril in the treatment of mild to moderate hypertension. (0 citation(s)) 105517/154 Phase 1 The effect of oral carvedilol 6.25mg, 12.5mg, 25mg and 50mg on exercise-induced tachycardia and blood pressure in healthy volunteers. (0 citation(s)) 105517/155 Phase 1 Determination of alpha and beta blockade thresholds for carvedilol in comparison to 400mg labetalol in healthy volunteers. (1 citation(s)) 105517/162 Phase 1 A randomised, double-blind, placebo-controlled, 21-day repeat dose parallel group study to assess the irritancy of intranasal administration of BRL 4910F mupirocin 5% nasal spray in healthy volunteers. (0 citation(s)) 105517/163 Phase 3 A pilot study on the efficacy and the safety of carvedilol in the elderly. (0 citation(s)) 105517/164 Phase 2 A double blind, randomized, placebo controlled trial to assess the efficacy of mupirocin in eradicating the nasopharyngeal colonization with Streptococcus pneumoniae, Haemophilus influenzae and/or Moraxella catarrhalis. (1 citation(s)) 105517/177 Phase 1 A pharmacokinetic study of a single oral dose of carvedilol 25mg administered to healthy elderly males compared to the same dose given to healthy young males. (0 citation(s)) 105517/220 Phase 3 A six-month, double-blind, placebo-controlled, multicenter dose-ranging comparison of oral carvedilol b.i.d. in patients with congestive heart failure, NYHA Class II-IV. (4 citation(s)) 105517/221 Phase 3 A six-month, double-blind, multicenter comparison of oral carvedilol b.i.d. with placebo in patients with congestive heart failure, NYHA Class II-IV. (2 citation(s)) 105517/223 Phase 3 A randomized trial of carvedilol (a beta-adrenergic antagonist with vasodilator properties) in patients with ischemic congestive cardiomyopathy. (2 citation(s)) 105517/233 Phase 1 Single- and Multiple-Dose Pharmacokinetics of Carvedilol and Enantiomers of Carvedilol in Patients with Congestive Heart Failure Compared to Normal Volunteers. (0 citation(s)) 105517/234 Phase 1 A study to determine the effect of carvedilol on the anticoagulant effect of warfarin and on the pharmacokinetics of warfarin enantiomers. (1 citation(s)) 105517/236 Phase 1 Multiple dose Pharmacokinetics of Carvedilol and its Enantiomers in Patients with Congestive Heart Failure. (1 citation(s)) 105517/239 Phase 3 A six-month, double-blind, multicenter comparison of oral carvedilol b.i.d. with placebo in patients with severe congestive heart failure, NYHA Class III-IV. (0 citation(s)) 105517/240 Phase 3 A twelve-month double-blind multicenter comparison of oral carvedilol b.i.d. with placebo in patients with mild congestive heart failure, NYHA Class II-III. (0 citation(s)) 105517/269 Phase 3 A multi-national, multi-centre, randomized, double-blind, parallel-group study to determine the effects of carvedilol on mortality and morbidity in patients with left ventricular dysfunction, with or without clinical evidence of heart failure, post myocardial infarction. (4 citation(s)) 105517/287 Phase 3 Carvedilol Prospective Randomized Cumulative Survival Trial. (39 citation(s)) 105517/321 Phase 4 A multicenter, placebo-controlled, 8-month study of the effect of twice daily carvedilol in children with congestive heart failure due to systemic ventricular systolic dysfunction (3 citation(s)) 105517/346; 105517/347 Phase 4 A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (Protocol 346) and A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on ... (9 citation(s)) 105517/367 Phase 3 A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Administration of Modified Release COREG or Placebo on Blood Pressure in Essential Hypertension Patients (2 citation(s)) 105517/369 Phase 3 An open, nonrandomized comparison of pharmacokinetic profiles of carvedilol (SK&F-105517) MR and IR on repeat dosing in chronic CHF subjects and survivors of an acute MI and LVD (0 citation(s)) 105517/396 Phase 4 A multicenter, open-label extension study to evaluate the safety of twice daily oral carvedilol in pediatric subjects with chronic heart failure (including results of Study 321 Open Label phase [321OL]) (0 citation(s)) 105517/902 Phase 1 A Randomized, Double-Blind, Placebo-Controlled, PK/PD Modeling, Multicenter Study to Compare the B1-Blocking Effects of an investigational formulation of carvedilol to COREG Immediate Release Tablets at Steady-State in Adult Patients with Essential Hypertension, by Evaluating Heart Rate Response ... (0 citation(s)) 105517/906 Phase 1 An Open-label, Single Dose, Three Session, Partially Randomized, Crossover Study to Assess Morning and Evening Dosing of Carvedilol Phosphate MR Capsules in Healthy Adult Subjects (0 citation(s)) 105517/908 Phase 1 A randomized, single-blind, placebo-controlled, three-period parallel-group study to assess the pharmacokinetic and pharmacodynamic relationship of a 50 mg single oral dose of immediate release carvedilol in healthy subjects (0 citation(s)) 105533 Phase 1 A randomized, open-label, single-dose, four-period cross-over study to evaluate the relative bioavailability of four formulations of GSK lisinopril compared to Zestril, and to compare over-encapsulated Zestril to Zestril (0 citation(s)) 106904 Phase 1 A Randomized, Open-Label, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics of Carvedilol CR (0 citation(s)) 111198 phase 4 Use of Beta-blockers and risk of new onset diabetes (1 citation(s)) 111944 n\a A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic reaction/ angioedema (0 citation(s)) 113834 n\a Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin (0 citation(s)) 114522 n\a A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic reaction/angioedema-Updated Analysis (1 citation(s)) 115478 n\a PGx 377: Pharmacogenetic evaluation of the association of functional variation in ADRB1 and ADRB2 genes with tolerability to carvedilol in the Phase I/II study CRV110734 (0 citation(s)) CAR 8902 Phase 1 Report of a study to assess the effects of inhibition and induction of hepatic mixed function oxidase activity on the pharmacokinetics of a single oral dose of carvedilol in 8 healthy volunteers. (0 citation(s)) CAR-02 Phase 1 A Study of the Pharmacodynamics and Pharmacokinetics of Intravenous Carvedilol in Normal Volunteers. (2 citation(s)) CFD105453 Phase 3 See Detailed Description (0 citation(s)) CFD109701 phase 1 A study to evaluate the potential incidence of orthostatic hypotension in elderly hypertensive patients following administration of a combination of carvedilol CR and lisinopril (1 citation(s)) COR100216 phase 3 See Detailed Description (2 citation(s)) COR103560 Phase 3 A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria (0 citation(s)) COR103561 phase 3 A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) with Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients (0 citation(s)) COR111096 phase 3 COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either carvedilol CR + lisinopril or lisinopril Monotherapy (1 citation(s)) CRV110734 phase 1 A study to evaluate the safety and tolerability of SK&F-105517-D in patients with chronic heart failure- An open-label study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of SK&F-105517-D in patients with chronic heart failure (Phase I/II study) (1 citation(s)) INT-CAR-13 Phase 3 Effect of carvedilol as compared to an ACE-inhibitor (enalapril) on hypertension and “quality of life” related well-being. (1 citation(s)) SK&F-105517/321 Phase 3 A multicenter, placebo-controlled, 8-month study of the effect of twice daily carvedilol in children withcongestive heart failure due to systemic ventricular systolic dysfunction (2 citation(s))
